Result: Extension of survival rate vs. expected survival rate

Expected and Actual Survival Months with Relative Failed Lines of Chemo and # Cycles of HEATT®

Ovarian results chart.png

The following data showing the extension of life expectancy supports the assertion of the effectiveness of Verthermia®’s approach to whole-body hyperthermia. With the average Expected Survival Months of 7.82 months across all 10 patients, the actual resulting average Survival Months of 596 days (19.7 months) in this HEATT® study shows the effectiveness of HEATT® to extend life. This increase in survival was correlated with the number of HEATT®-cycles - the greater the number of HEATT® cycles, the longer the patients survived.